These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 16286242)
1. A signaling role for dystrophin: inhibiting skeletal muscle atrophy pathways. Glass DJ Cancer Cell; 2005 Nov; 8(5):351-2. PubMed ID: 16286242 [TBL] [Abstract][Full Text] [Related]
2. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Acharyya S; Butchbach ME; Sahenk Z; Wang H; Saji M; Carathers M; Ringel MD; Skipworth RJ; Fearon KC; Hollingsworth MA; Muscarella P; Burghes AH; Rafael-Fortney JA; Guttridge DC Cancer Cell; 2005 Nov; 8(5):421-32. PubMed ID: 16286249 [TBL] [Abstract][Full Text] [Related]
3. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. Judge LM; Haraguchiln M; Chamberlain JS J Cell Sci; 2006 Apr; 119(Pt 8):1537-46. PubMed ID: 16569668 [TBL] [Abstract][Full Text] [Related]
4. [The cellular effects of functional unloading and passive stretch on m. soleus of dystrophin-deficient mdx mice]. Turtikova OV; Altaeva EG; Tarakina MV; Malashenko AM; Nemirovskaia TL; Shenkman BS Tsitologiia; 2008; 50(2):132-9. PubMed ID: 18540193 [TBL] [Abstract][Full Text] [Related]
5. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. Dogra C; Changotra H; Wergedal JE; Kumar A J Cell Physiol; 2006 Sep; 208(3):575-85. PubMed ID: 16741926 [TBL] [Abstract][Full Text] [Related]
6. Myoblast models of skeletal muscle hypertrophy and atrophy. Sharples AP; Stewart CE Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):230-6. PubMed ID: 21460719 [TBL] [Abstract][Full Text] [Related]
7. The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice. Anderson CL; De Repentigny Y; Cifelli C; Marshall P; Renaud JM; Worton RG; Kothary R Mol Ther; 2006 Nov; 14(5):724-34. PubMed ID: 16807118 [TBL] [Abstract][Full Text] [Related]
8. Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. Batchelor CL; Winder SJ Trends Cell Biol; 2006 Apr; 16(4):198-205. PubMed ID: 16515861 [TBL] [Abstract][Full Text] [Related]
9. Role of IGF-I in skeletal muscle mass maintenance. Clemmons DR Trends Endocrinol Metab; 2009 Sep; 20(7):349-56. PubMed ID: 19729319 [TBL] [Abstract][Full Text] [Related]
10. The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. Moore-Carrasco R; García-Martínez C; Busquets S; Ametller E; Barreiro E; López-Soriano FJ; Argilés JM FEBS Lett; 2006 Jan; 580(2):691-6. PubMed ID: 16412434 [TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle: increasing the size of the locomotor cell. Karagounis LG; Hawley JA Int J Biochem Cell Biol; 2010 Sep; 42(9):1376-9. PubMed ID: 20541033 [TBL] [Abstract][Full Text] [Related]
15. The pivotal role of cytokines in muscle wasting during cancer. Argilés JM; Busquets S; López-Soriano FJ Int J Biochem Cell Biol; 2005 Oct; 37(10):2036-46. PubMed ID: 16105746 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Argilés JM; López-Soriano FJ; Busquets S Curr Opin Support Palliat Care; 2007 Dec; 1(4):293-8. PubMed ID: 18685378 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting. Swiderski K; Shaffer SA; Gallis B; Odom GL; Arnett AL; Scott Edgar J; Baum DM; Chee A; Naim T; Gregorevic P; Murphy KT; Moody J; Goodlett DR; Lynch GS; Chamberlain JS Hum Mol Genet; 2014 Dec; 23(25):6697-711. PubMed ID: 25082828 [TBL] [Abstract][Full Text] [Related]
18. Dystrobrevins in muscle and non-muscle tissues. Rees ML; Lien CF; Górecki DC Neuromuscul Disord; 2007 Feb; 17(2):123-34. PubMed ID: 17251025 [TBL] [Abstract][Full Text] [Related]
19. Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Heydemann A; McNally EM Trends Cardiovasc Med; 2007 Feb; 17(2):55-9. PubMed ID: 17292047 [TBL] [Abstract][Full Text] [Related]
20. Processing and assembly of the dystrophin glycoprotein complex. Allikian MJ; McNally EM Traffic; 2007 Mar; 8(3):177-83. PubMed ID: 17274800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]